Merck & Co., Inc. (MRK): what the price requires

At today's price, Merck & Co., Inc. (MRK) is priced for +6.2% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-13 · Source: https://boothcheck.com/report/MRK

Headline

FieldValue
TickerMRK
CompanyMerck & Co., Inc.
Current price$124.03/sh
CompositionKeytruda 49% / Keytruda Qlex 0% / Alliance revenue - Lynparza 2% / Alliance revenue - Lenvima 2% / Welireg 1% / Alliance revenue - Reblozyl 1% / Gardasil/Gardasil 9 8% / ProQuad/M-M-R II/Varivax 4% / Vaxneuvance 1% / Capvaxive 1% / RotaTeq 1% / Pneumovax 23 0% / Bridion 3% / Prevymis 2% / Zerbaxa 0% / Dificid 0% / Winrevair 2% / Alliance revenue - Adempas/Verquvo 1% / Adempas 0% / Ohtuvayre 0% / Lagevrio 1% / Isentress/Isentress HD 1% / Delstrigo 0% / Pifeltro 0% / Belsomra 0% / Simponi 0% / Remicade 0% / Januvia 2% / Janumet 1% / Other pharmaceutical 4% / Animal Health - Livestock 6% / Animal Health - Companion Animal 4% / Other 1%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed11.8%
Operating margin today21.7%
Margin compression implied-9.9pp
Implied growth6.2%
Multiple paid25x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 7.1% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~8.7pp.

Reconcile: at the x-ray's 9.3% required return this reads ~23.4%/yr; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.01σ
cohort percentile (of 112 peers)62
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.72x4expensive
Earnings3.06x3expensive
Relative1.28x2expensive
Growth1.34x4expensive

Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.1%); the inversion above states its own rate.

Per-Model Detail (n=13)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$94.481.31xyesFCF base $14.1B, growth 3% (input: historical growth), terminal g 2.9%, WACC 8.1%, 5yr projection
DCF Exit MultipleGrowth$116.021.07xyesExit EV/EBITDA: 601.1x / 603.1x / 605.1x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$89.281.39xyesP/E 24x (sector median), scenarios: 20.3x / 24.0x / 27.7x (bear / base = sector held flat / bull), EV/EBITDA 35.2x
Simple DDMGrowth——no—
Two-Stage DDMGrowth$9.6612.84xyesStage 1: -34% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$39.083.17xyesBV/sh $18.56, ROE (TTM) 19.5%, ke 9.3%
Two-Stage Excess ReturnAsset$56.072.21xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$90.571.37xyesRev $65.8B, growth 3% (input: historical growth; tapered), Terminal P/S: 3.9x / 4.7x / 5.4x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset$54.642.27xyesBV $18.56 + 5yr PV of (ROE (TTM) 19.5% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$38.503.22xyes√(22.5 × EPS $3.55 × BVPS $18.56) — Graham's conservative floor
EV/EBITDA RelativeRelative$0.0112403.00xyesEBITDA $0.58B × sector EV/EBITDA 16.0x (excluded from median)
FCF YieldEarnings$44.012.82xyesFCF $14115.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$40.473.06xyesSBC-adj FCF $13.30B (FCF $14.12B − SBC $0.81B) capitalized at Kₑ
Ben Graham FormulaEarnings$2.9841.62xyesEPS $3.55 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$106.421.17xyesRevenue $65.77B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings$38.383.23xyesEPS $3.55 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$45.7b
Net debt / NOPAT (after-tax)4.10x
Net debt / operating income (pre-tax)3.24x
Interest coverage9.9x
Share count CAGR (buyback)-0.6%
Burning cashno

Bullet Takeaways

At $113.90 (as of June 27, 2026) Merck trades close to where the standard methods land, with the DCF and peer multiples clustering near $89 to $106. It is a roughly fairly valued large-cap pharma, not a deep discount.

The balance sheet funds the bridge over the patent cliff. Merck generated about $14.1 billion of trailing free cash flow, runs interest coverage near 9.3x, and carries net debt of about $45.7 billion at a manageable 3.2x operating income. That cash is the resource paying for the pipeline that has to replace Keytruda.

The defining risk is regulatory and concentration. Keytruda topped $8 billion in the quarter and goes off patent in 2028, and the entire sector faces government price pressure, so the bet is whether Winrevair, Animal Health, and 20-plus new launches can offset the loss of the biggest oncology drug in the world.

Bull Case

The balance sheet is the foundation of the bull case, because the patent cliff is a financing-and-pipeline problem and Merck has the resources to solve it. The company produced about $14.1 billion of trailing free cash flow, carries interest coverage near 9.3x, and holds net debt of roughly $45.7 billion against that cash flow, a manageable 3.2x operating income. Trailing return on equity near 19.5% on a modest book shows how much cash the franchise throws off. This is a company with the runway to invest through a transition, fund a growing dividend, and pursue business development, all from operations rather than from a stretched balance sheet.

The cash is already buying the replacement growth. Q1 2026 revenue rose 5% to $16.3 billion, and the standouts were the new products: Winrevair, for a rare and deadly lung condition, grew 88% to $525 million with peak-sales estimates of $5 to $7 billion, and Merck cited over 20 new product launches plus a breakout quarter for Winrevair. Even Keytruda itself is still growing, up 12% to $8.03 billion and beating estimates, while the more convenient injectable Keytruda Qlex begins to build a base to defend the franchise past 2028. The filing shows the deal-making engine working alongside the pipeline, with alliance revenue including "a $150 million upfront payment received and $175 million of regulatory approval milestones" on a single program (FY2025 10-K, accession 0000310158-26-000063).

The diversification is real and the valuation does not demand heroics. Animal Health, vaccines including Gardasil, and the new launches give Merck multiple growth vectors beyond oncology, and the segment carrying the priced-in premium is Animal Health, not Keytruda. On the standard methods the price is near fair: DCF Perpetual Growth at $94, DCF Exit Multiple at $106, P/Sales at $106, and the reverse-DCF reasonable band runs to a base near $131. For a buyer who believes the pipeline and Animal Health offset the Keytruda decline, the bull case is a cash-rich, diversified pharma trading around fair value with the financial strength to manage its own cliff.

Bear Case

The dominant risk is regulatory and external, and it sits on top of a revenue base concentrated in one drug. The entire pharmaceutical sector faces escalating government price pressure, and Merck's own filing lists "pricing pressures in the public and private sectors, both in the U.S. and abroad, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid" as a core risk to results (FY2025 10-K, accession 0000310158-26-000063). Drug-price negotiation under federal law targets exactly the high-revenue products Merck depends on, and unlike a competitive setback, a legislated price cut is not something execution can fix. This is the variable with the most leverage on the thesis, and the current price does not obviously discount it.

Layered on the regulation is the Keytruda cliff. Keytruda is the single largest revenue source, topping $8 billion in the quarter, and it loses U.S. patent protection in 2028. The filing is candid about how exclusivity erodes, warning of "reductions and product displacements, even for products protected by patents" as competing compounds proliferate (accession 0000310158-26-000063). The injectable Qlex version is meant to defend the franchise, but at $128 million in the quarter it is a fraction of the base it must replace. The Two-Stage dividend-discount method in the model assumes a 34% stage-one decline precisely because the market is bracing for the post-2028 drop.

The valuation offers a thin cushion against that combination. At $113.90 the price sits modestly above several growth and relative methods (DCF Perpetual at $94, Relative Valuation at $89), and well above the earnings-power and asset methods (FCF yield at $44, Earnings Power frames in the high $30s to high $50s). International sales already declined 11% in 2025 (accession 0000310158-26-000063), and the segment carrying the priced-in premium, Animal Health, sits at the very top of its peer distribution, a multiple only about 26% of comparable fast-growers have sustained.

Valuation

Lead with the segment carrying the priced-in premium: Animal Health. The decomposition shows the price embeds operating growth held near its self-funding ceiling for about eight years in that segment, computed at a 7% cost of capital, a multiple that sits at the very top of its peer distribution and that only about 26% of comparable fast-growers have sustained. That is the demanding part of the bet. The much larger pharmaceutical base, dominated by Keytruda, is priced more conservatively, which is the model's way of saying the market is leaning on the smaller, faster-growing pieces to carry the premium while it discounts the cliff in the core.

The whole-company X-ray lands near fair. The growth and relative methods cluster just below to just above the price: DCF Perpetual Growth at $94, DCF Exit Multiple at $106, P/Sales at $106, Relative Valuation at $89, and Discounted Future Market Cap at $81. The asset and earnings-power methods are lower, with Residual Income at $55, Two-Stage Excess Return at $56, and FCF yield at $44, because they capitalize current cash without crediting the pipeline. The reverse-DCF reasonable band runs from roughly $111 to $248 with a base near $131, so the current price sits at the low end of that range.

The synthesis is a fairly valued large-cap with a binary overhang. On the methods that credit continued growth, Merck is worth roughly what it trades for, and the base of the reverse-DCF band sits modestly above the price. On the methods that price only what it earns today, it looks expensive. The gap between them is the pipeline-and-Animal-Health premium, and the load-bearing question is whether Winrevair, the new launches, and Animal Health grow fast enough to offset Keytruda after 2028. The price is consistent with that working; it is not a discount that pays you to wait for proof.

Catalysts

The Q1 2026 print, reported April 30, 2026, is the key recent event: revenue of $16.3 billion up 5%, with Keytruda up 12% to $8.03 billion (beating estimates) and Winrevair up 88% to $525 million, against a one-time Cidara-related charge that hit reported results (CNBC; TIKR). Management pointed to over 20 new product launches and a breakout Winrevair quarter as evidence the diversification engine is scaling.

The forward set is dominated by the patent cliff and pipeline ramp. The swing factors into the coming years are the pace of Winrevair adoption toward its $5 to $7 billion peak estimate, the uptake of injectable Keytruda Qlex ahead of the 2028 loss of exclusivity, Animal Health growth, contributions from new launches such as Capvaxive, and the outcome of government drug-price negotiations. Analyst sentiment is steady, with a consensus target near $118 (high $139) and a December 2025 upgrade to $130 from BMO Capital (Simply Wall St; Yahoo Finance). The defining question each quarter is whether the broader base can keep guiding higher even as Keytruda approaches its cliff.

Sources: Merck Q1 2026 results (CNBC, April 2026; TIKR); Simply Wall St launch and guidance coverage; Yahoo Finance and Alphastreet diversification analysis (2026).

Peer Cohorts (Per Segment, With Filing Citations)

Pharmaceutical (reported)

Animal Health (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive MRK report on boothcheck